HomeCompareBAX vs TROW

BAX vs TROW: Dividend Comparison 2026

BAX yields 2.23% · TROW yields 5.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TROW wins by $218.6K in total portfolio value
10 years
BAX
BAX
● Live price
2.23%
Share price
$16.12
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.05
Full BAX calculator →
TROW
TROW
● Live price
5.67%
Share price
$90.09
Annual div
$5.11
5Y div CAGR
38.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$239.2K
Annual income
$101,174.52
Full TROW calculator →

Portfolio growth — BAX vs TROW

📍 TROW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXTROW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + TROW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
TROW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$189.83/yr
After 10yr DRIP, annual income (after tax)
$8.54/yr
TROW
Annual income on $10K today (after 15% tax)
$482.13/yr
After 10yr DRIP, annual income (after tax)
$85,998.34/yr
At 15% tax rate, TROW beats the other by $85,989.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + TROW for your $10,000?

BAX: 50%TROW: 50%
100% TROW50/50100% BAX
Portfolio after 10yr
$129.9K
Annual income
$50,592.29/yr
Blended yield
38.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BAX right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+22.5% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
TROW
Analyst Ratings
8
Buy
24
Hold
6
Sell
Consensus: Hold
Price Target
$106.25
+17.9% upside vs current
Range: $94.00 — $115.00
Altman Z
7.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
11
TROW buys
12
PoliticianChamberTickerTypeAmountDate
Michael McCaul🏢 House$BAX▲ Buy$50,001 - $100,0002026-01-13
Lisa McClain🏢 House$BAX▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$BAX▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$BAX▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$BAX▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$BAX▲ Buy$1,001 - $15,0002025-09-25
Ro Khanna🏢 House$BAX▼ Sell$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$BAX▼ Sell$1,001 - $15,0002025-09-03
Ro Khanna🏢 House$BAX▲ Buy$1,001 - $15,0002025-08-26
Ro Khanna🏢 House$BAX▼ Sell$1,000 - $15,0002025-08-12
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXTROW
Forward yield2.23%5.67%
Annual dividend / share$0.36$5.11
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%38.2%
Portfolio after 10y$20.6K$239.2K
Annual income after 10y$10.05$101,174.52
Total dividends collected$590.00$202.1K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$19.75$106.25

Year-by-year: BAX vs TROW ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrTROW PortfolioTROW Income/yrGap
1← crossover$10,863$163.03$11,484$783.89$621.00TROW
2$11,744$120.82$13,450$1,162.69$1.7KTROW
3$12,655$89.12$16,151$1,758.89$3.5KTROW
4$13,607$65.52$20,009$2,727.85$6.4KTROW
5$14,607$48.06$25,775$4,364.97$11.2KTROW
6$15,665$35.20$34,841$7,262.24$19.2KTROW
7$16,787$25.75$49,960$12,679.24$33.2KTROW
8$17,981$18.83$76,939$23,482.29$59.0KTROW
9$19,254$13.76$129,033$46,708.18$109.8KTROW
10$20,612$10.05$239,240$101,174.52$218.6KTROW

BAX vs TROW: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

TROWStock

T. Rowe Price Group, Inc. is a publicly owned investment manager. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It launches and manages equity and fixed income mutual funds. The firm invests in the public equity and fixed income markets across the globe. It employs fundamental and quantitative analysis with a bottom-up approach. The firm utilizes in-house and external research to make its investments. It employs socially responsible investing with a focus on environmental, social, and governance issues. It makes investment in late-stage venture capital transactions and usually invests between $3 million and $5 million. The firm was previously known as T. Rowe Group, Inc. and T. Rowe Price Associates, Inc. T. Rowe Price Group, Inc. was founded in 1937 and is based in Baltimore, Maryland, with additional offices in Colorado Springs, Colorado; Owings Mills, Maryland; San Francisco, California; New York, New York; Philadelphia, Pennsylvania; Tampa, Florida; Toronto, Ontario; Hellerup, Denmark; Amsterdam, The Netherlands; Luxembourg, Grand Duchy of Luxembourg; Zurich, Switzerland; Dubai, United Arab Emirates; London, United Kingdom; Sydney, New South Wales; Hong Kong; Tokyo, Japan; Singapore; Frankfurt, Germany, Madrid, Spain, Milan, Italy, Stockholm, Sweden, Melbourne, Australia, and Amsterdam, Netherlands.

Full TROW Calculator →
📬

Get this BAX vs TROW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.